| INTRODUCTION
Severe haemophilia (factors VIII or IX <1%) is a lethal disease left untreated. This is not the case in resource-constrained countries, which comprise 70% of the world's population, and by extension, up to 70% of the world's individuals with haemophilia, leaving the majority undiagnosed with high morbidity and mortality due to uncontrolled bleeding. [5] [6] [7] [8] In lower income countries, based upon World Bank economic ratings, less than 10% of the patients have been identified. 9 Of those diagnosed globally, only 30% have access to clotting factor, resulting in a short life expectancy of 70% of the identified patients and presumed substantial mortality among those not identified. [6] [7] [8] The World Federation of Hemophilia (WFH) provides training programmes for healthcare providers and persons with haemophilia on the comprehensive care model for haemophilia and for the development of advocacy skills. It has been challenging to obtain government commitments to fund Haemophilia Treatment Centers (HTC) and purchase lower cost clotting factors. The provision of small donations of clotting factor to individual countries has often not been sufficient impetus to convince governments to support haemophilia programmes and even basic on-demand therapy for life-threatening bleeds.
Life expectancies in Western Europe
The WFH currently represents 134 national member patient organizations (NMOs) worldwide. An annual global survey is conducted to assess the amount of clotting factor utilized as a function of the total population (per capita). 9 This approach to quantify intracountry usage assumes a similar global incidence of haemophilia. Through this process, an estimate for I.U. of clotting factor required from basic survival to full prophylaxis can be estimated.
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In resource-rich countries, prophylactic use of factor VIII in children and adults is the standard of care 10, 11 and clotting factor concentrates (CFC) up to ~10 I.U. per capita are now available. 9 In contrast, in resource-constrained countries which WFH targets for humanitarian aid, per capita use is often well below 1 I.U. per capita, a disparity directly responsible for the observed high mortality. 7 The recent European Directorate for Quality of Medicine (EDQM) recommendation calls for minimum 4 I.U. per capita] to provide a prophylaxis strategy to minimize arthropathy. 12 We present the first fullyear results of the expanded WFH Humanitarian Aid Programme (HAP) in 58 countries consuming <1 I.U. per capita in clotting factor. 
| HUMANITARIAN AID PROGRAMME MATERIALS AND METHODS

| Goals of the programme
| Selection criteria
Countries were selected on the basis of the Annual Global Survey of clotting factor usage of <1 I.U./capita 9 
| Logistics
Based on an approved distribution plan, the manufacturer ships prod- 
| Training
WFH training materials were prepared for the expanded programme, including factsheets on storage and handling, administration and dosage, disposal of material, inhibitor detection, low-dose prophylaxis, monitoring for adverse events and product recall instructions. These factsheets are supplemented by frequent telephone and email contact and periodic regional and in-country visits. In the visits, training is generally conducted over 2 days by WFH staff and volunteers and includes didactic information on managing haemophilia as well as case reports and case series from recipient physicians on how the product has been utilized.
| Key performance indicators
An online reporting system was developed to identify the actual product needs in real time and to provide product utilization metrics in each country. A series of Key Performance Indicators (KPI) were identified to reflect the degree of success in product utilization and the purpose for which product was used in patients. Dosing and usage of products is the responsibility of the treating physician, and no individual patient outcome data are collected. Thus, ethics committee approvals were not needed.
| RESULTS
Since 1996 (Table 1) . By 2014, multiyear agreements were signed with several manufacturers and plasma collection agencies for prospective, multiyear donations.
These donations were used primarily for emergency situations and
were not sufficient for routine on-demand therapy, non-emergent orthopaedic reconstructive surgeries or prophylactic regimens. The majority of the major manufacturers do not contribute to a prospective humanitarian aid programme, despite owning the majority of the worldwide market.
In 2014, two companies, Bioverativ (formerly Biogen) and Sobi, announced a contribution of 1 billion I.U. of extended half-life (EHL)
clotting factor to the worldwide bleeding disorders community over 10 years (Table 1) reached, relative to the total number identified in a country, is listed in Figure 2 .
To establish the countries most in need of aid, data from the annual global survey were utilized. 9 This approach to quantify intracountry usage assumes a similar global incidence of haemophilia; thus, differences in prevalence based upon early death and lack of patient identification do not impact the results. Through this process, an estimate for I.U. of clotting factor required for basic survival to full prophylaxis can be estimated. (Table 2) . Importantly 6 governments, Senegal, Egypt, Sri Lanka, Nigeria, Armenia and Kenya, have made commitments to increase their support of in-country haemophilia programmes.
In 2016, treatment of acute bleeding episodes represented the single largest category of utilization, followed by prophylaxis and surgery ( Figure 3A and B). Surgeries fell off later in the year, likely due to completion of some backlogged reconstructive orthopaedic and circumcision cases ( Figure 3C ).
By year end 2016, 42 195 acute bleeding episodes had been treated, which included 3% intracranial and 2% intra-abdominal bleeding sites, considered life-threatening ( Figure 3B ). Of the 675 surgeries reported, 7% were for pseudotumors and 3% were for intracranial haemorrhages ( Figure 3C ), both considered as life-saving or limb-saving procedures. to episodic treatment producing considerably inferior results. [13] [14] [15] When transition to prophylaxis is made, it has led to less use of product for acute bleeding, which should be reflected in reporting in future years.
| DISCUSSION
Challenges within HTCs in the recipient countries are high, and include lack of laboratory instrumentation and lack of requisite lab reagents. 16, 17 The influx of 10-100-fold more clotting factor into many countries has necessitated the need for new training programmes for the haematologists, surgeons and nurses, as well as laboratory personnel, for management of patients receiving ongoing infusions.
In these environments, there is a predilection to treat only major emergency bleeding episodes and a reluctance to start young children on low-dose prophylaxis or immune tolerance therapy due to fear that a sufficient supply of product will be unpredictable. However, increased confidence in the continuing prospective availability of sufficient clotting factor is an incentive to improve care and management, and importantly, to perform outreach clinics and diagnose many new cases that now still die from bleeding. [18] [19] [20] HTCs are instructed to keep records and report on the usage of every donated vial. Currently, 68% of all donated product in 2016 have been reported; some product has not yet been utilized.
A programme of this scope and magnitude has significant limitations. Although product is being distributed to 58 countries under 1 I.U. per capita FVIII, another 15 countries in this category lack sufficient infrastructure to benefit from the programme. This is due to a lack of haemophilia-specific medical expertise and as a consequence no identified patients. In addition, home care therapy has not yet become a standard of practice, and many patients are unable to benefit as they lack access the treatment centre due to distance or transportation constraints. Crucial for the continuation of the HA programme is closing the circle between donation and treatment. The WFH wants to create a reliable and complete system in close collaboration with the centres that are benefitting from the programme.
It is important to recognize that the WFH HAP is a means to- Outcome data which reflect the management of patients are not currently being collected. In 2018, the WFH will initiate outcome data T A B L E 2 Key Performance Indicators (KPI) for product utilization before and after expansion of the WFH Humanitarian Aid Programme collection of individual patients through a new project the World Bleeding Disorders Registry (WBDR). 22 While it will be worldwide and applicable to all levels of economic development, it is also intended to capture outcome data from many of the HTCs receiving humanitarian aid through collection of anonymous individual patient data following informed consent.
One question that arises is whether donations of ~130 million I.U. per year are sufficient. As the prevalence of identified cases in the countries receiving the donations is generally very low and few patients are on prophylaxis or home care therapy, supply appears to be adequate at present. However, with increasingly more aggressive treatment of bleeding, low-dose prophylaxis, development of home treatment and increasing numbers of new patients, demand will outstrip supply. If increased quantities were available, expansion of low-dose prophylaxis to more patients would be a high priority.
Towards this end, numerous models of corporate partnerships have been successfully explored in recent years within the pharmaceutical company and disaster relief settings. [23] [24] [25] While these ventures likely are not all purely altruistic, both pharma executives and academicians have concluded it is both good business sense and a corporate responsibility to collaborate with non-profits to alleviate human suffering.
With improved manufacturing technologies, costs of protein production are low, and the yearly donations still amount to a very small proportion of total yearly sales of clotting factor (<2%). As only a minority of manufacturers donate product, much more recognition of these dual mutually beneficial goals is needed. For the biopharma companies supporting the expanded WFH HAP the scope coupled with the financial magnitude of the programme is unprecedented in global health care. 
